Product image of Irinotecan Accord (Irinotecan) supplied by GNH India

Irinotecan Accord

Active Ingredient:
Irinotecan
Origin:
EU

Irinotecan Accord (Irinotecan)

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an intravenous formulation for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer, targeting tumor cells that rely on topoisomerase I activity.

GNH India supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use, including both private and public health systems.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Irinotecan is a topoisomerase I inhibitor used in colorectal cancer chemotherapy.
  • Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine therapy.
  • Advanced colorectal cancer: reduces tumor burden in patients with disease progression.
  • Colorectal cancer (adjuvant setting): investigated in clinical trials for high‑risk patients.

How It Works

  • Irinotecan is converted intracellularly to its active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. This binding prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage, replication arrest, and ultimately tumor cell death.

Side Effects

Irinotecan may cause a range of adverse reactions.

Common Side Effects

  • Neutropenia: reduced white blood cell count increasing infection risk.
  • Diarrhea: often severe and may require antidiarrheal therapy.
  • Nausea and vomiting: typical chemotherapy‑related symptoms.
  • Alopecia: hair loss that is usually reversible.
  • Fatigue: generalized tiredness during treatment.
  • Anemia: decreased red blood cell levels.

Serious or Rare Side Effects

  • Febrile neutropenia: fever with low neutrophil count requiring urgent care.
  • Severe colitis: intense inflammation of the colon.
  • Cholinergic syndrome: abdominal cramps, sweating, and bradycardia.
  • Hypersensitivity reactions: rash, itching, or anaphylaxis.
  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Pulmonary toxicity: rare lung inflammation.

Precautions & Warnings

Before initiating Irinotecan therapy, clinicians should assess patient-specific factors.

  • Hepatic function: adjust dose in patients with liver impairment.
  • Blood counts: monitor complete blood count regularly for neutropenia.
  • Hydration: ensure adequate fluid intake to mitigate severe diarrhea.
  • Concomitant CYP3A4 inhibitors: avoid strong inhibitors that may increase exposure.
  • Pregnancy: use only if potential benefit justifies potential risk to the fetus.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Irinotecan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise SN‑38 levels.
  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
  • Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): increased bleeding risk.
  • Other myelosuppressive agents: additive bone‑marrow suppression.
  • Fluoroquinolones: potential for enhanced neutropenia.
  • Loperamide: may mask early signs of severe diarrhea.

Frequently Asked Questions

Irinotecan Accord contains the chemotherapeutic agent irinotecan, which is indicated for the treatment of metastatic and advanced colorectal cancer. It works as part of a chemotherapy regimen to target rapidly dividing tumor cells.

Irinotecan is converted to the active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. This prevents the re‑ligation of single‑strand DNA breaks during replication, leading to DNA damage, cell‑cycle arrest, and tumor cell death.

The dose of Irinotecan Accord is determined by the prescribing oncologist based on the patient’s clinical condition, body surface area, and treatment protocol. Specific dosing regimens are not disclosed here and should follow the prescriber’s instructions.

Irinotecan is classified as a prescription‑only antineoplastic agent and may pose risks to a developing fetus or nursing infant. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, after thorough medical evaluation.

To place an order, submit an enquiry on the Irinotecan Accord product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as oxaliplatin (a platinum‑based drug) or fluoropyrimidines. It is often combined with fluoropyrimidines for synergistic effect and is chosen based on tumor genetics, prior therapy, and patient tolerance.

Irinotecan Accord should be stored at 2‑8 °C, kept refrigerated, protected from light, and should not be frozen or shaken. Follow the manufacturer’s instructions for reconstitution and handling in a sterile environment.

Irinotecan Accord is administered intravenously by a qualified healthcare professional. The infusion is typically given over a set period, as directed by the treatment protocol, and may be combined with other chemotherapy agents.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, cholinergic syndrome, and rare hypersensitivity reactions. Prompt medical attention is required if any of these symptoms occur.

Patients with known hypersensitivity to irinotecan or its components, severe hepatic impairment, uncontrolled infections, or those receiving contraindicated drug combinations should not use Irinotecan Accord. The prescribing physician will assess suitability on an individual basis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Irinotecan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT